Drug manufacturer InnoGenerics acquired.
Ofichem Group is going to produce medicines: `We want to go from powders to pills`
The Active Pharmaceutical Ingredients market comprises the largest segment of the Indian pharmaceutical sector. India is the third-largest Pharmaceutical APIs market in Asia-Pacific. As per the BusinessWire report, the Indian API Market stood at USD 11806.93 million in FY 2021 and will grow at a CAGR of 12.24% during the forecast period. The Indian API Market is segmented based on the synthesis, source, therapeutic application, drug type, company, and region. Out of the various therapeutic categories, we will discuss 11 trending therapeutic categories of APIs and their uses. All the therapeutic categories, pharmacologic class, and formulary key drug types are available on the FDA website, and their scientific definitions are available on the Britannica website. However, we have delineated some of the most prominent APIs that rule the markets and are always in demand.
Last Friday, September 24, our new R&D facility and a new QC laboratory were officially opened by the mayor of the municipality of Westerwolde, Mr. Jaap Velema. This was done under the watchful eye of all staff members and invited guests. The invitees included all the people who contributed to the establishment of these new laboratories.
The Netherlands is too dependent on the production of medicines in China and India. That says Weite Oldenziel, CEO of Ofichem from Ter Apel. In a magazine of the University of Groningen, he argues in favor of bringing the production of commonly used medicines back to Europe, even if there are snags. The Ofichem Group makes active ingredients for medicines, among other things, and the company also trades in raw materials for medicines. It is one of the last Dutch – and European – companies that still produces raw materials for medicines.
Ofipharma and Ofichem have managed to bring in additional stock of Propofol ampoules to the Netherlands, thanks to their global network and the unique collaboration between the Ministry of Health (VWS) and the National Medicines Coordination Centre (LCG). As such they were able to make an important contribution in securing the availability of this medicine for Dutch ICUs. Propofol is an essential anaesthetic in the ventilation of COVID-19 patients.
Recently the building of our new state of the art R&D pilot plant started. At the same time we are also creating an extra laboratory for our QC department. Both R&D and QC are undergoing rapid growth, therefore it’s necessary to expand.
The successful performance of Ofidit, Lab Ofichem’s independent quality assurance company, results in enlargement of their manpower the last years. Together with the experienced purchase staff of Ofichem B.V., the location is suitable for future growth.
Los laboratorios Pierre Fabre España pondrán a disposición de hospitales y residencias de ancianos 19.000 unidades de geles hidroalcohólicos. Por otro lado, 20.000 unidades de estos geles llegarán a las farmacias para su venta bajo la marca Ducray, a un precio recomendado de 3 euros los 100 militros. El personal de las plantas de producción y envasado de dermocosméticos Pierre Fabre de Francia y Brasil se han movilizado para producir geles hidroalcohólicos que serán distribuidos en España, Italia, Alemania, Francia y Brasil.